TCRT Alaunos Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%
Returns
ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5,000 | $10,000 | $5,000 | $2.92M | $398,000 |
| R&D expense | $1.36M | $362,000 | $16.28M | $25.02M | $49.64M |
| SG&A expense | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M |
| Operating income | -$4.22M | -$4.81M | -$34.27M | -$35.10M | -$77.55M |
| Interest expense | — | $0 | $1.92M | $3.15M | $1.19M |
| Income tax | $0 | — | — | — | — |
| Net income | -$4.18M | -$4.68M | -$4.68M | -$37.73M | -$78.75M |
| EBITDA | -$4.22M | -$4.81M | -$31.95M | -$32.35M | -$74.95M |
| EPS (basic) | -2.20 | -2.92 | -21.97 | -2.61 | -0.37 |
| EPS (diluted) | -2.20 | -2.92 | -21.97 | -2.61 | -0.37 |
| Weighted avg. shares (diluted) | 1.95M | 1.60M | 1.60M | 14.48M | 214.40M |
| Balance sheet | |||||
| Cash & equivalents | $1.39M | $1.09M | $6.06M | $53.00M | $76.05M |
| Receivables | $3,000 | $5,000 | $1,000 | $4,000 | $1.11M |
| Current assets | $1.99M | $2.75M | $8.26M | $53.80M | $78.83M |
| PP&E, net | $91,000 | $0 | $2,000 | $8.46M | $10.94M |
| Total assets | $2.97M | $2.75M | $8.26M | $64.94M | $94.86M |
| Current liabilities | $813,000 | $692,000 | $1.96M | $24.17M | $16.04M |
| Short-term debt | — | — | $0 | $16.77M | $7.87M |
| Long-term debt | — | $0 | $0 | $0 | $16.25M |
| Total debt | — | $0 | $0 | $16.77M | $24.12M |
| Total liabilities | $813,000 | $692,000 | $1.96M | $26.38M | $36.81M |
| Shareholders' equity | $2.15M | $2.06M | $6.31M | $38.55M | $58.06M |
| Net debt | — | -$1.09M | -$6.06M | -$36.23M | -$51.94M |
| Shares outstanding | 2.35M | 1.60M | 1.60M | 16.03M | 216.13M |
| Cash flow statement | |||||
| Operating cash flow | -$2.87M | -$4.97M | -$30.14M | -$29.23M | -$61.47M |
| Capital expenditure | $98,000 | $0 | $197,000 | $216,000 | $3.32M |
| Free cash flow | -$2.97M | -$4.97M | -$30.34M | -$29.45M | -$64.79M |
| Investing cash flow | -$98,000 | $0 | $1.35M | -$193,000 | -$3.32M |
| Financing cash flow | $3.26M | $0 | -$18.14M | $6.37M | $25.78M |
| Depreciation & amortization | $7,000 | $2,000 | $2.31M | $2.76M | $2.60M |
| Stock-based compensation | $796,000 | $435,000 | $2.80M | $3.53M | $10.77M |
| Share buybacks | — | — | $0 | $45,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.